Advertisement
Research Article| Volume 28, ISSUE 8, P728-732, October 15, 1990

Tryptophan treatment of aggressive psychiatric inpatients

Open AccessDOI:https://doi.org/10.1016/0006-3223(90)90459-F
Tryptophan treatment of aggressive psychiatric inpatients
Previous ArticleEEG and CT findings in patients with panic disorder
Next ArticleThe effect of diagnostic methodology on the sensitivity of the TRH stimulation test for depression: A literature review
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      This double-blind, placebo-controlled study tested the effectiveness of tryptophan (TRP) in the treatment of aggressive psychiatric inpatients. After a baseline observation period of 1 month, patients were randomly assigned to treatment either with TRP (up to 6 g/day) or with placebo. There were 10 subjects in each treatment group. These treatments were administered for 25–35 days, after which the patients were observed for 1 month. Throughout this study, patients were receiving other medications. Injections of antipsychotics and sedatives were administered as needed to control agitated or violent behavior. Blood levels of TRP and other large neutral amino acids were obtained repeatedly, and ratios between TRP and other amino acids were computed. These analyses confirmed significant increases of TRP ratios in TRP-treated patients. TRP treatment had no effect on the number of violent incidents, but it significantly reduced the need for injections of antipsychotics and sedatives. The study thus provided indirect support for beneficial effects of TRP in aggressive psychiatric inpatients.

      References

        • Bidlingmeyer B.A.
        • Cohen S.A.
        • Tarvin T.L.
        Rapid analysis of amino acids using pre-column derivitization.
        J Chromatogr. 1984; 336: 93-104
        • Bioulac B.
        • Benezich M.
        • Renaud B.
        • Noel B.
        • Roche D.
        Serotonergic function in the 47, XYY syndrome.
        Biol Psychiatry. 1980; 15: 917-923
        • Blevins W.L.
        • Hertzman P.
        • Ting M.
        • et al.
        Fosinophilia-myalgia syndrome-New Mexico.
        JAMA. 1989; 262: 3116
        • Branchey M.
        • Branchey M.
        • Shaw S.
        • Lieber C.S.
        Depression, suicide, and aggression in alcoholics and their relationship to plasma amino acids.
        Psychiatry Res. 1984; 12: 219-226
        • Brown G.L.
        • Goodwin F.K.
        • Ballenger J.C.
        • Goyer P.F.
        • Major L.F.
        Aggression in humans correlates with cerebrospinal fluid amine metabolites.
        Psychiatry Res. 1979; 1: 131-139
        • Coccaro E.F.
        • Siever L.J.
        • Klar H.M.
        • et al.
        Serotonergic studies in patients with affective and personality disorders.
        Arch Gen Psychiatry. 1989; 46: 587-599
        • Fernstrom J.D.
        • Wurtman R.J.
        Brain serotonin content: Physiological regulation by plasma neutral amino acids.
        Science. 1972; 178: 414-416
        • Guy W.
        ECDEU Assessment Manual for Psychopharmacology.
        National Institute of Mental Health, Rockville, MD1976
        • Linnoila M.
        • Virkkunen M.
        • Scheinin M.
        • Nuutila A.
        • Rimon R.
        • Goodwin F.K.
        Low cerebrospinal fluid 5-hydroxyindoleacetic acid concentration differentiates impulsive from nonimpulsive violent behavior.
        Life Sci. 1983; 33: 2609-2614
        • Morand C.
        • Young S.N.
        • Ervin F.R.
        Clinical response of aggressive schizophrenics to oral tryptophan.
        Biol Psychiatry. 1983; 18: 575-578
        • O'Neil M.
        • Page N.
        • Adkins W.N.
        Tryptophan-trazodone treatment of aggressive behavior.
        Lancet. 1986; ii: 859-860
        • Richardson M.A.
        • Suckow R.
        • Whittaker R.
        • et al.
        Boulton A.A. Jurio A.V. Downer R.G.M. Phenylalanine, phenylethylamine and tardive dyskinesia in psychiatric patients in trace amines: Comparative and clinical neurobiology. Humana Press, Clifton, NJ1988: 409-422
        • Slutsker L.
        • Hoesly F.C.
        • Miller L.
        • Williams L.P.
        • Watson J.C.
        Eosinophilia-myalgia syndrome associated with exposure to tryptophan from a single manufacturer.
        JAMA. 1990; 264: 213-217
        • Virkkunen M.
        • De Jong J.
        • Bartko J.
        • Goodwin F.K.
        • Linnoila M.
        Relationship of psychobiological variables to recidivism in violent offenders and impulsive fire setters.
        Arch Gen Psychiatry. 1989; 46: 600-603

      Article info

      Publication history

      Received in revised form: February 17, 1990
      Received: October 20, 1989

      Identification

      DOI: https://doi.org/10.1016/0006-3223(90)90459-F

      Copyright

      © 1990 Published by Elsevier Inc.

      User license

      Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0) |
      How you can reuse Information Icon
      Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0)

      Permitted

      For non-commercial purposes:

      • Read, print & download
      • Redistribute or republish the final article
      • Text & data mine
      • Translate the article (private use only, not for distribution)
      • Reuse portions or extracts from the article in other works

      Not Permitted

      • Sell or re-use for commercial purposes
      • Distribute translations or adaptations of the article

      Elsevier's open access license policy

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX